ClinicalTrials.gg
RecruitingNCT06235112AI INFORMUpdated Jan 23, 2026

AI Detection of Incidental Coronary Artery Calcium to Enhance Cardiovascular Disease Prevention

An interventional study of Electronic health record-based notification of Nanox.AI Coronary Artery Calcification Assessment in Coronary Artery Disease, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,500
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Coronary Artery Disease by Brigham and Women's Hospital — 2 open to participants now, 3 under way, none of them phase 3. Coronary Artery Disease · Brigham and Women's Hospital.

Planned enrollment
3rd of 12
1,500 · median 163
Started
2024
the only one that year
No phase
6 of 18
1 open now
Registered
17th of 18
by date

Among the 18 studies in Coronary Artery Disease by Brigham and Women's Hospital, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is one of 6 with no phase, and was the 17th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

2 of the 18 studies in Coronary Artery Disease by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Coronary Artery Disease by Brigham and Women's Hospital, or all of them as a file.
02

Study summary

AI INFORM is a multicenter randomized trial that will test the hypothesis that providing clinicians information on the presence and amount of coronary artery calcifications (CAC), will result in initiation or intensification of preventive therapies. The study will use a cloud-based artificial intelligence (AI) platform (Nanox.AI) that can analyze non contrast chest CT and estimate the amount of CAC.

03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 40-75 with prior chest CT within last 3 years

Exclusion criteria

Exclusion Criteria:

  • Prior coronary artery disease
  • Prior cancer
  • Other life-limiting condition
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    Notification of Coronary Artery Calcification

    Notification to providers of the presence of coronary artery calcification automatically detected by AI based device (software) on chest CT. Recommendation of preventive therapy.

    Device: Electronic health record-based notification of Nanox.AI Coronary Artery Calcification Assessment

  • No intervention
    Non-notification of Coronary Artery Calcification

    No notification to providers of the presence of coronary artery calcification on chest CT automatically detected by AI based device (software) on chest CT. No recommendation of preventive therapy.

Interventions

  • DeviceElectronic health record-based notification of Nanox.AI Coronary Artery Calcification Assessment

    The intervention involves electronic health record, email, or letter notification about the presence of coronary artery calcification on chest CT and recommendation of preventive therapy. This is based on results of the automatic detection of coronary artery calcification from AI device (software).

06

What researchers measure

Primary outcomes

  1. Proportion of participants with initiation or intensification of lipid-lowering therapy after intervention

    Initiation or intensification of therapy (yes/no) by 6 months after the intervention. Initiation: starting lipid-lowering therapy; intensification: increasing the dose of lipid-lowering therapy

    Time frame: 6 months

Secondary outcomes

  1. Average change in LDL-C after intervention

    Average quantitative change in LDL-C (low-density lipoprotein cholesterol) between baseline and 12 months after intervention

    Time frame: 12 months

  2. Proportion of participants with downstream invasive or noninvasive testing after intervention

    Composite outcome: Downstream testing (yes/no) including coronary artery calcium score, coronary CT angiography, invasive coronary angiography, or stress testing by 12 months after the intervention.

    Time frame: 12 months

  3. Proportion of participants with major adverse cardiovascular events after intervention

    Composite outcome: Occurrence of an adverse cardiovascular event (yes/no) including cardiovascular death, myocardial infarction, or stroke by 12 months after the intervention

    Time frame: 12 months

  4. Proportion of participants with initiation or intensification of other preventive therapies after intervention

    Initiation or intensification of preventive therapy (yes/no) by 6 months after the intervention. Preventive therapy includes any of the following: aspirin, antihypertensive therapy, metabolic therapy. Initiation: starting preventive therapy; intensification: increasing the dose of preventive therapy

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No IPD will be shared

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jun 2027, 34 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 34 months is close to that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2024
First posted
Jan 31, 2024
StartActual
Jul 31, 2024
Primary completionEst.
Jun 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06235112
Collaborators
Nano-X Imaging Limited
Responsible party
Daniel Michael Huck, MD, MPH (Principal Investigator, Brigham and Women's Hospital) — Principal investigator
First posted
Jan 31, 2024
Start date
Jul 31, 2024
Primary completion
Jun 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Jan 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion